Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3541860 · 1 trial · 1 indication
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3541860 (Part A) | EXPERIMENTAL | Single doses of LY3541860 administered intravenously (IV) or subcutaneously (SC). |
| LY3541860 (Part B) | EXPERIMENTAL | Multiple doses of LY3541860 administered either IV or SC. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Single doses of Placebo administered either IV or SC. |
| Placebo (Part B) | PLACEBO_COMPARATOR | Multiple doses of Placebo administered either IV or SC. |
| Name | Type | Description |
|---|---|---|
| LY3541860 | DRUG | Administered either IV or SC. |
| Placebo | DRUG | Administered either IV or SC. |
Inclusion Criteria: * Are male or female not of childbearing potential * Have a body weight between 18 and 32 kilograms per square meter (kg/m²) and a body weight ≥ 50 kilograms (kg) * Have veins suitable for blood sampling Exclusion Criteria: * Have or used to have health problems or laboratory ...
LY3541860 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy adult participants, including Japanese and non-Japanese volunteers. The specific disease or condition it is intended to treat has not been disclosed.
LY3541860 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound conducted in Japan.
LY3541860 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational agent and has not been approved by the FDA for any indication.
LY3541860 has been evaluated in one completed Phase 1 trial, NCT05042310, titled A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants. The trial enrolled 94 healthy volunteers in Japan, was randomized, double-blind, and placebo-controlled, and included participants aged 20 years and older.
LY3541860 has been studied only in healthy volunteers in a Phase 1 trial, so no therapeutic indication has been disclosed. It is an investigational small molecule and is not approved for any use. Its clinical development remains at the earliest stage.